The 2022 annual report, outlining the current development pipeline of new drug-based treatments for Parkinson’s, has been published.
Cure Parkinson’s is funding Professor Oliver Bandmann at the University of Sheffield to establish a nationwide infrastructure for a study group focused specifically on conducting clinical trials for Parkinson’s.
The findings of the phase 1a clinical trial of Anle138b have been published. Anle138b is a new drug that targets the build-up of alpha synuclein, a protein that clumps together in Parkinson’s.
This research led by Professor Joe Mazzulli, will, it is hoped, give us a better understanding of how lonafarnib can reduce the build-up of the toxic protein alpha-synuclein which is a characteristic of Parkinson’s.
Researchers from Cedars Sinai Hospital, Los Angeles have presented their initial top line results of the liraglutide trial, co-funded by Van Andel Institute and Cure Parkinson’s, at the recent American Association of Neurology annual meeting. The results indicate that liraglutide improves aspects of daily living…